Causes and countermeasures of waste in clinical research of Chinese medicine_Chinese Journal of Evidence-Based Medicine

Authors：

YANG Fengwen , JI Zhaochen , ZHANG Mingyan , PANG Wentai , WANG Hucheng , ZHENG Wenke ,  ZHANG Junhua

Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, P.R.China;

Corresponding author：

ZHANG Junhua, Email: zjhtcm@foxmail.com

Keywords：

Research waste; Traditional Chinese medicine; REWARD

DOI：

10.7507/1672-2531.201807109

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The issue of waste in medical research has been widely concerned in recent years. Research waste is also significant in the field of traditional Chinese medicine (TCM). This study summarized the causes of research waste in TCM and provided suggestions to researchers and administrators for reducing research waste and promoting rational use of medical research resources.

Citation： YANG Fengwen, JI Zhaochen, ZHANG Mingyan, PANG Wentai, WANG Hucheng, ZHENG Wenke, ZHANG Junhua. Causes and countermeasures of waste in clinical research of Chinese medicine. Chinese Journal of Evidence-Based Medicine, 2018, 18(11): 1212-1215. doi: 10.7507/1672-2531.201807109 Copy

1.	Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet, 2009, 374(9692): 1341-1345.
2.	Chalmers I, Bracken MB, Djulbegovic B, et al. How to increase value and reduce waste when research priorities are set. Lancet, 2014, 383(9912): 156-165.
3.	Ioannidis JP, Greenland S, Hlatky MA, et al. Increasing value and reducing waste in research design, conduct, and analysis. Lancet, 2014, 383(9912): 166.
4.	Salman AS, Beller E, Kagan J, et al. Increasing value and reducing waste in biomedical research regulation and management. Lancet, 2014, 383(9912): 176-185.
5.	Chan AW, Song F, Vickers A, et al. Increasing value and reducing waste: addressing inaccessible research. Lancet, 2014, 383(9913): 257.
6.	Glasziou P, Altman DG, Bossuyt P, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet, 2014, 383(9913): 267.
7.	THE LANCET. Available at: https://www.thelancet.com/campaigns/efficiency/statement.
8.	张俊华, 李幼平, 张伯礼. 循证中医药学: 理论与实践. 中国中药杂志, 2018, 43(1): 1-7.
9.	王家莹, 田贵华, 张莉, 等. 中医药系统评价/Meta分析结果的引证现状调查. 兰州大学学报(医学版), 2016, 42(1): 48-54.
10.	Lund H, Brunnhuber K, Juhl C, et al. Towards evidence based research. BMJ, 2016, 355: i5440.
11.	王桂倩, 孙塑伦, 谢雁鸣, 等. 中医临床研究方案设计常见问题及其优化措施. 中华中医药杂志, 2017, 32(3): 935-938.
12.	毛兵, 王刚, 陈小东, 等. 《中国中西医结合杂志》发表随机对照试验报告的质量评价. 中国循证医学杂志, 2006, 6(4): 297-304.
13.	常静, 李廷谦, 万美华, 等. 中国4种中医药大学学报随机对照临床试验文献的质量评价. 中国循证医学杂志, 2006, 6(3): 171-178.
14.	张明妍, 杨丰文, 李越, 等. 《中国中西医结合杂志》刊载中医药随机对照试验报告质量的研究. 中国循证医学杂志, 2017, 17(3): 357-363.
15.	Gargon E, Gurung B, Medley N, et al. Choosing important health outcomes for comparative effectiveness research: a systematic review. PLoS One, 2014, 9(6): e99111.
16.	张明妍, 张俊华, 张伯礼. 2015年中药治疗稳定性心绞痛临床试验结局指标文献研究. 中国中西医结合杂志, 2018, 38(2): 191-197.
17.	Taichman DB, Sahni P, Pinborg A, et al. Data sharing statements for clinical trials. BMJ, 2017, 357(23): 2372.
18.	吴泰相, 米娜瓦尔·阿不都, 郝园, 等. 中国临床试验注册10年: 现状与问题. 中国循证医学杂志, 2018, 18(6): 522-525.
19.	Xing DM, Sun Y, Zhu MJ, et al. The status of IRBs/ECs, ICFs and trial registration in clinical trials of traditional Chinese medicine for stable angina. Int J Cardiol, 2014, 174(2): 396-397.
20.	吴泰相, 卞兆祥, 李幼平, 等. 临床试验原始数据透明化与共享:关于医学研究伦理的哲学命题及其对临床试验的意义. 中国循证医学杂志, 2018, 18(6): 538-542.
21.	陈耀龙, 周奇, 崔荣荣, 等. 基于AGREE Ⅱ的中医药临床指南质量评价. 中国循证医学杂志, 2016, 16(11): 1331-1337.
22.	ClinicalTrials. gov. Available at: http: //www. clinicaltrials. gov/.
23.	中国临床试验注册中心. Available at: http: //www. chictr. org. cn/index. aspx.
24.	郑文科. 发挥中医药优势, 应对感染性疾病挑战--第二届循证中医药学国际论坛成功举行. 天津中医药, 2017, 34(5): 289-290.
25.	邢冬梅, 张俊华, 张伯礼. 中医临床研究核心结局指标集形成路径. 中华中医药杂志, 2014, 29(5): 1352-1355.
26.	COMET Initiative. Available at: http://www.comet-initiative.org/.
27.	张伯礼: 以核心指标集研究为切入点推动中医药临床研究质量提升. Available at: http://www.xinhuanet.com/health/2018-01/31/c_1122347918.htm.
28.	Kirkham JJ, Gorst S, Altman DG, et al. COS-STAR: a reporting guideline for studies developing core outcome sets (protocol). Trials, 2015, 16(1): 373.
29.	中医药临床证据数据库. Available at: http://www.adrade.cn/evidence/index.
30.	发挥中医药优势应对感染性疾病挑战. Available at: http://news.xinhuanet.com/health/2017-04/25/c_1120868927.htm.

1. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet, 2009, 374(9692): 1341-1345.
2. Chalmers I, Bracken MB, Djulbegovic B, et al. How to increase value and reduce waste when research priorities are set. Lancet, 2014, 383(9912): 156-165.
3. Ioannidis JP, Greenland S, Hlatky MA, et al. Increasing value and reducing waste in research design, conduct, and analysis. Lancet, 2014, 383(9912): 166.
4. Salman AS, Beller E, Kagan J, et al. Increasing value and reducing waste in biomedical research regulation and management. Lancet, 2014, 383(9912): 176-185.
5. Chan AW, Song F, Vickers A, et al. Increasing value and reducing waste: addressing inaccessible research. Lancet, 2014, 383(9913): 257.
6. Glasziou P, Altman DG, Bossuyt P, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet, 2014, 383(9913): 267.
7. THE LANCET. Available at: https://www.thelancet.com/campaigns/efficiency/statement.
8. 张俊华, 李幼平, 张伯礼. 循证中医药学: 理论与实践. 中国中药杂志, 2018, 43(1): 1-7.
9. 王家莹, 田贵华, 张莉, 等. 中医药系统评价/Meta分析结果的引证现状调查. 兰州大学学报(医学版), 2016, 42(1): 48-54.
10. Lund H, Brunnhuber K, Juhl C, et al. Towards evidence based research. BMJ, 2016, 355: i5440.
11. 王桂倩, 孙塑伦, 谢雁鸣, 等. 中医临床研究方案设计常见问题及其优化措施. 中华中医药杂志, 2017, 32(3): 935-938.
12. 毛兵, 王刚, 陈小东, 等. 《中国中西医结合杂志》发表随机对照试验报告的质量评价. 中国循证医学杂志, 2006, 6(4): 297-304.
13. 常静, 李廷谦, 万美华, 等. 中国4种中医药大学学报随机对照临床试验文献的质量评价. 中国循证医学杂志, 2006, 6(3): 171-178.
14. 张明妍, 杨丰文, 李越, 等. 《中国中西医结合杂志》刊载中医药随机对照试验报告质量的研究. 中国循证医学杂志, 2017, 17(3): 357-363.
15. Gargon E, Gurung B, Medley N, et al. Choosing important health outcomes for comparative effectiveness research: a systematic review. PLoS One, 2014, 9(6): e99111.
16. 张明妍, 张俊华, 张伯礼. 2015年中药治疗稳定性心绞痛临床试验结局指标文献研究. 中国中西医结合杂志, 2018, 38(2): 191-197.
17. Taichman DB, Sahni P, Pinborg A, et al. Data sharing statements for clinical trials. BMJ, 2017, 357(23): 2372.
18. 吴泰相, 米娜瓦尔·阿不都, 郝园, 等. 中国临床试验注册10年: 现状与问题. 中国循证医学杂志, 2018, 18(6): 522-525.
19. Xing DM, Sun Y, Zhu MJ, et al. The status of IRBs/ECs, ICFs and trial registration in clinical trials of traditional Chinese medicine for stable angina. Int J Cardiol, 2014, 174(2): 396-397.
20. 吴泰相, 卞兆祥, 李幼平, 等. 临床试验原始数据透明化与共享:关于医学研究伦理的哲学命题及其对临床试验的意义. 中国循证医学杂志, 2018, 18(6): 538-542.
21. 陈耀龙, 周奇, 崔荣荣, 等. 基于AGREE Ⅱ的中医药临床指南质量评价. 中国循证医学杂志, 2016, 16(11): 1331-1337.
22. ClinicalTrials. gov. Available at: http: //www. clinicaltrials. gov/.
23. 中国临床试验注册中心. Available at: http: //www. chictr. org. cn/index. aspx.
24. 郑文科. 发挥中医药优势, 应对感染性疾病挑战--第二届循证中医药学国际论坛成功举行. 天津中医药, 2017, 34(5): 289-290.
25. 邢冬梅, 张俊华, 张伯礼. 中医临床研究核心结局指标集形成路径. 中华中医药杂志, 2014, 29(5): 1352-1355.
26. COMET Initiative. Available at: http://www.comet-initiative.org/.
27. 张伯礼: 以核心指标集研究为切入点推动中医药临床研究质量提升. Available at: http://www.xinhuanet.com/health/2018-01/31/c_1122347918.htm.
28. Kirkham JJ, Gorst S, Altman DG, et al. COS-STAR: a reporting guideline for studies developing core outcome sets (protocol). Trials, 2015, 16(1): 373.
29. 中医药临床证据数据库. Available at: http://www.adrade.cn/evidence/index.
30. 发挥中医药优势应对感染性疾病挑战. Available at: http://news.xinhuanet.com/health/2017-04/25/c_1120868927.htm.

Previous Article
The application of regression discontinuity design in clinical therapeutic research
Next Article
Analysis of real world studies on traditional Chinese medicine in China

Chinese Journal of Evidence-Based Medicine

Causes and countermeasures of waste in clinical research of Chinese medicine

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content